U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07225712) titled 'A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia' on Nov. 05.
Brief Summary: To evaluate the safety of SEP-363856 (75 mg/day or 100 mg/day) administered for 52 weeks in adult participants with schizophrenia
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: SEP-363856
Tablet, once daily, for 52 weeks
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Otsuka Pharmaceutical Co., Ltd.
Disclaimer: Curated by HT Syndication....